Financial Snapshot

Revenue
$401.1M
TTM
Gross Margin
59.37%
TTM
Net Earnings
$32.64M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
820.14%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$209.9M
Q3 2024
Cash
Q3 2024
P/E
74.25
Dec 02, 2024 EST
Free Cash Flow
-$120.5M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Revenue $241.6M $93.46M $30.26M $25.64M $23.60M $13.02M $7.690M $6.210M
YoY Change 158.53% 208.83% 18.03% 8.62% 81.33% 69.27% 23.83%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Revenue $241.6M $93.46M $30.26M $25.64M $23.60M $13.02M $7.690M $6.210M
Cost Of Revenue $87.53M $28.19M $9.103M $9.004M $9.741M $7.280M $5.550M $5.440M
Gross Profit $154.1M $65.27M $21.16M $16.64M $13.86M $5.730M $2.140M $770.0K
Gross Profit Margin 63.77% 69.84% 69.92% 64.88% 58.73% 44.02% 27.83% 12.4%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Selling, General & Admin $119.6M $69.90M $38.28M $24.19M $23.60M $12.32M $7.610M $8.120M
YoY Change 71.04% 82.58% 58.27% 2.51% 91.6% 61.83% -6.28%
% of Gross Profit 77.58% 107.09% 180.93% 145.4% 170.21% 214.92% 355.61% 1054.55%
Research & Development $36.06M $26.81M $22.30M $18.83M $19.87M $13.66M $14.96M $15.64M
YoY Change 34.47% 20.21% 18.45% -5.23% 45.5% -8.72% -4.35%
% of Gross Profit 23.4% 41.08% 105.41% 113.2% 143.33% 238.32% 699.07% 2031.17%
Depreciation & Amortization $8.177M $3.500M $1.800M $1.600M $1.222M $769.0K $630.0K $430.0K
YoY Change 133.63% 94.44% 12.5% 30.93% 58.91% 22.06% 46.51%
% of Gross Profit 5.31% 5.36% 8.51% 9.62% 8.81% 13.42% 29.44% 55.84%
Operating Expenses $182.8M $96.71M $60.59M $43.02M $43.47M $25.97M $22.56M $23.76M
YoY Change 89.04% 59.62% 40.84% -1.03% 67.36% 15.12% -5.05%
Operating Profit -$28.73M -$31.44M -$39.43M -$26.38M -$29.60M -$20.24M -$20.42M -$22.99M
YoY Change -8.62% -20.27% 49.44% -10.87% 46.28% -0.9% -11.18%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Interest Expense $10.79M $3.726M -$4.751M $3.985M $4.353M $2.720M -$520.0K -$970.0K
YoY Change 189.61% -178.43% -219.22% -8.45% 60.04% -623.08% -46.39%
% of Operating Profit
Other Income/Expense, Net $2.056M -$4.728M -$4.751M -$2.332M -$3.904M -$3.478M $160.0K -$110.0K
YoY Change -143.49% -0.48% 103.73% -40.27% 12.25% -2273.75% -245.45%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Pretax Income -$26.67M -$36.17M -$44.18M -$28.72M -$33.67M -$23.92M -$20.79M -$24.07M
YoY Change -26.25% -18.14% 53.85% -14.71% 40.76% 15.05% -13.63%
Income Tax -$1.700M $66.00K $36.00K $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$25.00M -$36.20M -$44.20M -$28.70M -$33.55M -$23.76M -$20.82M -$24.07M
YoY Change -30.94% -18.1% 54.01% -14.45% 41.21% 14.1% -13.5%
Net Earnings / Revenue -10.35% -38.73% -146.06% -111.94% -142.12% -182.5% -270.74% -387.6%
Basic Earnings Per Share -$0.77 -$1.23 -$1.60 -$1.16
Diluted Earnings Per Share -$0.77 -$1.23 -$1.60 -$1.16 -$2.363M -$1.174M -$1.029M -$1.189M

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Cash & Short-Term Investments $394.8M $201.2M $92.45M $125.6M $80.70M $20.20M $24.70M
YoY Change 96.25% 117.61% -26.39% 55.64% 299.5% -18.22%
Cash & Equivalents $394.8M $201.2M $25.58M $24.60M $20.10M $20.20M $11.90M
Short-Term Investments $0.00 $66.87M $101.1M $60.60M $0.00 $12.70M
Other Short-Term Assets $8.031M $2.896M $5.460M $2.300M $1.500M $1.800M $500.0K
YoY Change 177.31% -46.96% 137.39% 53.33% -16.67% 260.0%
Inventory $44.24M $20.61M $14.86M $11.90M $11.20M $9.300M $8.000M
Prepaid Expenses
Receivables $63.58M $27.61M $5.934M $6.900M $6.600M $3.400M $900.0K
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $510.7M $252.3M $118.7M $146.8M $100.0M $34.80M $34.00M
YoY Change 102.4% 112.54% -19.14% 46.8% 187.36% 2.35%
Property, Plant & Equipment $180.5M $24.35M $15.69M $4.800M $4.800M $3.500M $2.500M
YoY Change 641.13% 55.23% 226.83% 0.0% 37.14% 40.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $562.0K $500.0K $500.0K $500.0K $500.0K $3.900M $500.0K
YoY Change 12.4% 0.0% 0.0% 0.0% -87.18% 680.0%
Total Long-Term Assets $195.4M $24.85M $16.19M $5.200M $5.300M $7.400M $3.000M
YoY Change 686.19% 53.53% 211.31% -1.89% -28.38% 146.67%
Total Assets $706.0M $277.1M $134.9M $152.0M $105.3M $42.20M $37.00M
YoY Change
Accounts Payable $12.72M $3.341M $6.651M $1.200M $7.200M $4.700M $3.500M
YoY Change 280.63% -49.77% 454.25% -83.33% 53.19% 34.29%
Accrued Expenses $40.26M $20.08M $16.34M $10.30M $8.300M $7.200M $5.000M
YoY Change 100.49% 22.91% 58.61% 24.1% 15.28% 44.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $1.800M
YoY Change -100.0%
Total Short-Term Liabilities $54.93M $23.66M $23.24M $11.90M $16.10M $12.60M $10.90M
YoY Change 132.17% 1.82% 95.28% -26.09% 27.78% 15.6%
Long-Term Debt $506.2M $58.70M $35.20M $34.70M $34.10M $33.70M $6.800M
YoY Change 762.42% 66.76% 1.43% 1.76% 1.19% 395.59%
Other Long-Term Liabilities $7.707M $7.415M $8.604M $1.600M $400.0K $1.700M $1.500M
YoY Change 3.94% -13.82% 437.75% 300.0% -76.47% 13.33%
Total Long-Term Liabilities $513.9M $66.11M $43.80M $36.30M $34.50M $35.40M $8.300M
YoY Change 677.35% 50.93% 20.66% 5.22% -2.54% 326.51%
Total Liabilities $568.8M $89.77M $67.04M $48.10M $50.70M $47.90M $19.20M
YoY Change 533.66% 33.91% 39.37% -5.13% 5.85% 149.48%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Basic Shares Outstanding 32.52M 29.56M 27.62M 24.70M
Diluted Shares Outstanding 32.52M 29.56M 27.62M 24.70M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $2.4235 Billion

About TransMedics Group, Inc.

TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 584 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.

Industry: Electromedical & Electrotherapeutic Apparatus Peers: ABBOTT LABORATORIES AtriCure, Inc. Cryoport, Inc. Integer Holdings Corp LEMAITRE VASCULAR INC NEVRO CORP Paragon 28, Inc. PROCEPT BioRobotics Corp TREACE MEDICAL CONCEPTS, INC.